Загрузка...
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
Immunotherapy has shown promising results in cancer treatment. Research shows that most patients might be resistant to these therapies. So, new immune therapies are needed. OX40 (CD134) and OX40 ligand (OX40L), costimulatory molecules, express on different types of immune cells. The interaction betw...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735535/ https://ncbi.nlm.nih.gov/pubmed/31564917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S214211 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|